Slide 1: Aurobindo Pharma Limited Earnings Presentation Q1FY27
Aurobindo Pharma Limited Earnings Presentation Q1FY27
Slide 2: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 3: Table of Content
Table of Content 04 Q1FY27 Business & Financial Highlights 11 Financial Summary Update on Biosimilars and 14 Biologics Contract Manufacturing 13 20 Filings Snapshot 3
Slide 4: Q1FY27 Business & Financial Highlights
Q1FY27 Business & Financial Highlights 4
Slide 5: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q1FY27 ₹ 9,150 Cr ₹ 1,924 Cr* ₹ 1,032 Cr Q1FY26 ₹ 7,868 Cr ₹ 1,603 Cr ₹ 824 Cr Y-o-Y growth % 16.3% 20.0% 25.2% *Operating EBITDA excluding one time impact of ₹43 Cr on account of derecognition of lease receivable (Refer Note-11 of Un
Slide 6: Business Highlights – Q1FY27
Business Highlights – Q1FY27 Revenue of ₹9,150 Cr with 16.3% growth Y-o-Y, driven by strong performance across all business areas, U.S. base business continued to grow driven by volume gains and new launches Operating EBITDA stood at ₹1,924 Cr with a margin of 21.0% Net Capex of US$ 78 million* prim
Slide 7: Quarterly Performance – Q1FY27
Quarterly Performance – Q1FY27 Revenue (₹ Cr.) EBITDA (₹ Cr.) 9,150 1,924* 8,853 8,646 1,792 1,773 1,801 8,382 8,286 1,678 7,868 1,603 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 PAT (₹ Cr.) Cash flows before dividend and buyback (US$ Mn) 1,032 131 903 910 921
Slide 8: Consolidated Business Performance
Consolidated Business Performance ₹ Cr Q1FY27 Q1FY26 Y-o-Y (%) Q4FY26 Q-o-Q (%) USA 3,770 3,488 8.1% 3,543 6.4% Europe 2,937 2,338 25.6% 2,795 5.1% Growth Markets* 1,063 772 37.7% 980 8.5% ARV 330 355 -6.9% 328 0.8% Total Formulations 8,101 6,953 16.5% 7,646 6.0% Beta-lactam 800 636 25.7% 918 -12.9%
Slide 9: US Formulations Business Performance Highlights
US Formulations Business Performance Highlights Revenue ex-gRevlimid (US$ Mn) Commentary 399 • US revenue in Q1FY27 accounted for 41.2% of 389 consolidated revenue. Ex-gRevlimid the revenue 381 grew by 5% Q-o-Q. The growth was driven by strong volume gains coupled with new launches during the quarte
Slide 10: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Cr.) 113 1,208 267 107 261 241 1,049 90 916 41 36 35 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Europe business posted ARV business revenue remained API revenues increase
Slide 11: Financial Summary
Financial Summary 11
Slide 12: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement ₹ Cr. Q1FY27 Q1FY26 Y-o-Y Chg. (%) Q4FY26 Q-o-Q Chg. (%) Revenue from Operations 9,150 7,868 16.3% 8,853 3.4% Gross Profit 5,523 4,629 19.3% 5,424 1.8% Gross Margin 60.4% 58.8% 153 bps 61.3% -91 bps Overheads -3,599 -3,025 18.9% -3,623 -0.6% Operating EBI
Slide 13: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-23 Mar-24 Mar-25 Mar-26 Jun-26 Closing Rate (INR/USD) 82.170 83.405 85.475 94.835 94.663 930 884 843 786 809 887 Fx Loan restated in INR 4,638 3,994 5,883 6,709 7,472 Rupee Loan 224 2,324 2,065 964 922 182 185 117 87 Gross Debt 4,862 6,318 7,9
Slide 14: Update on Biosimilars and Biologics Contract Manufacturing
Update on Biosimilars and Biologics Contract Manufacturing 14
Slide 15: CuraTeQ Biologics - Q1 FY27 Highlights
CuraTeQ Biologics - Q1 FY27 Highlights Continued execution across filings, market launches, and distribution alliances Regulatory & Filings Commercial Expansion Partnerships to Scale • ANVISA GMP certification secured: Successfully • UK — Full portfolio live: All four MHRA-approved • Expanded distri
Slide 16: Capacity Expansion & Portfolio Broadening
Capacity Expansion & Portfolio Broadening Building the manufacturing base and pipeline depth to sustain growth into 2030 10,000 L (4 × 2,500 L) mammalian cell-culture bioreactors, with integrated purification suites, being added Bioreactor Capacity Addition to existing capacity at CuraTeQ. Merger of
Slide 17: CuraTeQ's Biosimilars Pipeline Status
CuraTeQ's Biosimilars Pipeline Status Assets spanning oncology, respiratory, autoimmune and ophthalmology segments Brand / Code Molecule Segment Stage Status Detail DYRUPEG Pegfilgrastim Oncology Launched EMA, MHRA, HC approved & commercial ZEFYLTI Filgrastim Oncology Launched EMA, MHRA approved & c
Slide 18: Key Next-Wave Products to Sustain Momentum
Key Next-Wave Products to Sustain Momentum Large addressable markets underpin the post-2026 growth pipeline Code Key Indications '25 Rev. '30 Opp. BP31 Plaque Psoriasis, PsA, Ankylosing Spondylitis $6.7B $9.5B BP36 Atopic Dermatitis, Asthma $13.1B $22B BP30 Multiple Myeloma $14.4B $16B BP45 Ulcerati
Slide 19: TheraNym — Our Foray into Biologics Contract Manufacturing
TheraNym — Our Foray into Biologics Contract Manufacturing Anchored by a long-term partnership with Merck Sharp & Dohme (MSD) Unit 1 — Inaugurated The 2030 Vision Inaugurated on 3 June 2026. On track to begin qualification activities in November 2026, ahead of first commercial revenues. With Unit 1
Slide 20: Filings Snapshot
Filings Snapshot 20
Slide 21: US ANDA Filings Snapshot as on 30th June 2026
US ANDA Filings Snapshot as on 30th June 2026 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^^ CNS 166 35.0 Aurobindo (Excl. Specialty & 800 737 600 563 Specialty & Injectables 300 700 ARV 30 1.5 500 250 600 200 174 Injectables) 400 500 150 44.7 300 400 200 100 63 CVS 125 300 96 50 0.7
Slide 22: Thank You
Thank You For more information, contact: ir@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1211 2222